SABS (SAB Biotherapeutics) 6-Month Price Index: 0.90 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SABS SAB Biotherapeutics Inc SABS
32 GF Score
Price $3.39
GF Value $0.12
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics 6-Month Price Index?

SAB Biotherapeutics SABS -3.00% 32 6-Month Price Index is 0.90 as of Sep. 22, 2026. GuruFocus rates SABS with a GF Score™ of 32/100 and a GF Value™ of $0.12 (Significantly Overvalued). The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-22), SAB Biotherapeutics's 6-Month Price Index is 0.90.

SAB Biotherapeutics  (NAS:SABS) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

SAB Biotherapeutics 6-Month Price Index Related Terms

SABS vs AGEN, DMAC, STRO: 6-Month Price Index Comparison

For the Biotechnology subindustry, SAB Biotherapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SABS
32GF Score
SAB Biotherapeutics Inc SABS
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics  (NAS:SABS) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.90 mean?
SAB Biotherapeutics (SABS) has a 6-Month Price Index of 0.90 as of Sep. 22, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' 6-Month Price Index too high?
SAB Biotherapeutics' current 6-Month Price Index is 0.90. Overall, SAB Biotherapeutics has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' 6-Month Price Index compare to AGEN and DMAC?
SAB Biotherapeutics' 6-Month Price Index of 0.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current 6-Month Price Index is 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, SAB Biotherapeutics (SABS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.12, compared to a current price of $3.39 — trading 2725% above its estimated fair value. The current 6-Month Price Index is 0.90. SAB Biotherapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current 6-Month Price Index is 0.90 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SAB Biotherapeutics (SABS) Overvalued in 2026?

Based on GuruFocus' analysis, SAB Biotherapeutics stock appears to be overvalued. The current stock price of $3.39 is trading 2725% above its estimated GF Value™ of $0.12. GuruFocus considers SAB Biotherapeutics to be Significantly Overvalued.

Key valuation signals for SABS:

  • 6-Month Price Index: 0.90
  • GF Value™: $0.12 vs. price of $3.39 (2725% above fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the SABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
32GF Score

Get the complete analysis for SABS

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.39
Price
$0.12
GF Value